Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24730450
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Aspirin treatment improved mesenchymal stem cell immunomodulatory properties via
the 15d-PGJ2/PPAR?/TGF-?1 pathway
#MMPMID24730450
Tang J
; Xiong J
; Wu T
; Tang Z
; Ding G
; Zhang C
; Wang S
; Liu Y
Stem Cells Dev
2014[Sep]; 23
(17
): 2093-103
PMID24730450
show ga
Bone marrow mesenchymal stem cells (BMMSCs) have been used to treat a variety of
autoimmune diseases in clinics. However, the therapeutic effects are largely
dependent on the immunomodulatory capacity of culture-expanded BMMSCs. In the
present study, we show that aspirin (acetylsalicylic acid, ASA)-treated BMMSCs
have significantly improved immunomodulatory function, as indicated by
upregulation of regulatory T cells (Tregs) and downregulation of Th17 cells via
the 15d-PGJ2/PPAR?/TGF-?1 pathway. Furthermore, the therapeutic effect of
ASA-pretreated BMMSCs was confirmed in a dextran sodium sulfate-induced
experimental colitis mouse model, in which systemic infusion of ASA-pretreated
BMMSCs significantly ameliorated disease activity index and colonic inflammation,
along with an increased number of Tregs and decreased number of Th17 cells. Taken
together, our results suggest that aspirin treatment is a feasible strategy to
promote BMMSC-based immunomodulation.
free
free
free
